NCCR AntiResist

NCCR AntiResist

New approaches to combat antibiotic-resistant bacteria

NCCR AntiResist

NCCR AntiResist

New approaches to combat antibiotic-resistant bacteria

NCCR AntiResist

NCCR AntiResist

New approaches to combat antibiotic-resistant bacteria

Revitalizing antibiotic discovery by a patient-centered paradigm shift

Antibiotics are powerful and indispensable drugs to treat life threatening bacterial infections, such as sepsis or pneumonia. Antibiotics also play a central role in many other areas of modern medicine, in particular to protect patients with a weakened immune system during cancer therapies, transplantations or surgical interventions. These achievements are now at risk, with the fraction of bacterial pathogens that are resistant to one or more antibiotics steadily increasing.

The discovery and development of novel antibiotics faces complex societal, economic, technological and scientific challenges. The declining pipeline for novel antibiotics and increasing resistance to existing drugs gradually reduces the options clinicians have to treat bacterial infections.

NCCR AntiResist

The National Center of Competence in Research AntiResist aims to bring about a paradigm shift in antibiotic research with an interdisciplinary approach that assembles a Swiss-wide network of research groups from the fields of clinical research, biology, chemistry, computation, engineering and pharmacology.

The research program is structured into three four-year phases covering strategically and dynamically evolving milestones. Research activities center around a better understanding of pathogen physiology in patients; developing axenic and tissue-based model systems mimicking patient environments; and engineering of novel screening platforms for the next generation of antibiotics.

NCCR AntiResist is funded by the Swiss National Science Foundation, and the home institution is the University of Basel.

Watch our 3-Minute YouTube video produced by the University of Basel.

News and Events

#NCCRWomen Video Series

To celebrate Women's Day 2021 and the 50th Anniversary of women's right to vote in Switzerland, we are working with our sister NCCRs across the country to release a series of videos showcasing women working in science. The week of October 11-15 highlights female scientists at NCCR AntiResist: Nina Khanna, Vishwachi Tripathi, Ikram Salah, Valentina Cappelletti and Julia Boos.  You can watch the videos on YouTube or Instagram. Watch, share and be inspired! 

INCATE Launch

NCCR AntiResist is exited to announce the launch of INCATE: Incubator for Antibacterial Therapies Europe. INCATE (INCubator for Antibacterial Therapies in Europe) is launching on August 25th to support innovators in the fight against drug-resistant bacterial infections. INCATE is a partnership between academic members, industry, and other supporting partners. It will help to bridge the gap between research and industry for treatments, diagnostics and interventions that reduce the prevalence and impact of Antimicrobial Resistance (AMR).

Read more at their webpage here.

PNAS Paper

The latest PNAS paper from the Hiller and the Bumann labs is shaking the common assumptions on porins function, which may unravel new ways of facilitating antibiotic delivery into bacteria. Check out this great collaborative work here: https://doi.org/10.1073/pnas.2107644118

Ude, J., Tripathi, V., Buyck, J.M., Söderholm, S., Cunrath, O., Fanous, J., Claudi, B., Egli, A., Schleberger, C., Hiller, S., and Bumann, D. (2021) Outer membrane permeability: Antimicrobials and diverse nutrients bypass porins in Pseudomonas aeruginosa. PNAS 118:e2107644118

Novel antibiotics are urgently needed to resolve the current antimicrobial resistance crisis. For critical pathogens, such as Pseudomonas aeruginosa, drug entry through the cell envelope is one of the major challenges in the development of effective novel antibiotics. The Hiller and Bumann labs now show that almost all antibiotics and diverse hydrophilic nutrients bypass porins and instead permeate directly through the outer membrane lipid bilayer. By contrast, Pseudomonas needs porins for efficient utilisation of carboxylate-containing nutrients as carboxylate groups hinder bilayer penetration. As many current antibiotics carry carboxylate groups, these findings may lead us to re-consider our strategies when designing new antimicrobial molecules, and to identify new strategies for facilitating their delivery into bacteria.